Breakthrough for hepatitis vaccine.
The antibody, CB-Hep.1, is from an "ancestor" of the tobacco plant. It replaces an antibody obtained from mice in Cuba's manufacturing of the hepatitis B vaccine, researchers said, Carlos Borroto, deputy director at Cuba's Biotechnology and Genetic Engineering Center (CIGB) here, said the plantibody won approval from Cuba's medication quality control agency. CB-Hep.1 is the first plantibody authorized anywhere in the world for manufacturing a vaccine. It is just the second approved for human use, after one approved in the US for treating tooth decay;
The plantibody won approval on April 11 and is being used in manufacturing the vaccine. Borroto said "145 million doses have been exploited and not a single problem in their use has been reported." Cuba, he added, has several plantibody projects, including one to be used as a cancer treatment, from the same plant, noting that "a number of major international companies are looking for a partnership with us."
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||development of hepatitis B vaccine|
|Article Type:||Brief article|
|Date:||Aug 1, 2006|
|Previous Article:||Senior party leader jailed.|
|Next Article:||Backdoor route to U.S.|